| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| ln Vitro |
Foscarnet sodium (Phosphonoformic acid) reproduces the pyrophosphate leaving group of the nucleotide transfer reaction in order to block the human cytomegalovirus DNA polymerase (UL54)[1]. Influenza A Victoria (IC50=29 μM), Influenza B HK (IC50=61 μM), Avian Myeloblastosis Virus (IC50=5-8 μM), HSV-1, many strains (IC50=0.4-3.5 μM), and Foscarnet sodium (Trisodium Phosphoformate) are all inhibited by this medication[2].
|
|---|---|
| References |
[1]. Zahn KE, Doublié S, et al. Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase. J Biol Chem. 2011 Jul 15;286(28):25246-55.
[2]. Oberg B, et al. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).Pharmacol Ther. 1982;19(3):387-415. [3]. Hakki M, et al. Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.Curr Hematol Malig Rep. 2020 Jan 24. |
| Additional Infomation |
Trisodium foscarnet hexahydrate is the hexahydrate form of trisodium foscarnet. It is used as an antiviral drug to treat cytomegalovirus retinitis (CMV retinitis, an inflammation of the retina that can lead to blindness) and as an alternative to ganciclovir for HIV patients who require concurrent antiretroviral therapy but cannot tolerate ganciclovir due to blood toxicity. It is an antiviral drug. It is a hydrate and also a one-carbon compound. It contains trisodium foscarnet.
Sodium foscarnet is a prescription antiviral drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of cytomegalovirus (CMV) retinitis in HIV patients. Sodium foscarnet is also approved by the U.S. Food and Drug Administration (FDA) for the treatment of a specific type of herpes simplex virus infection called acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infection in people with compromised immune systems. Cytomegalovirus (CMV) disease (such as retinitis affecting the eye) and HSV disease can be opportunistic infections (OIs) of HIV. Sodium phosphonoformate is the trisodium salt of an inorganic pyrophosphate synthesized organic analog with antiviral activity. Sodium phosphonoformate selectively blocks the pyrophosphate binding site of herpesvirus-specific DNA polymerase without affecting the concentration of cellular DNA polymerase. This drug does not require phosphorylation by thymidine kinase (TK) or other kinases, and is therefore effective in vitro against herpes simplex virus (HSV) TK-deficient mutants and cytomegalovirus (CMV) UL97 mutants. Because sodium phosphonoformate can cross the blood-brain barrier, it can be used to treat viral infections of the central nervous system. Sodium phosphonoformate is an antiviral drug used to treat cytomegalovirus retinitis. Sodium phosphonoformate is also active against human herpesviruses and HIV. See also: Sodium phosphonoformate (note moved here). |
| Molecular Formula |
CH12NA3O11P
|
|---|---|
| Molecular Weight |
300.04
|
| Exact Mass |
299.981
|
| CAS # |
34156-56-4
|
| Related CAS # |
Foscarnet sodium;63585-09-1
|
| PubChem CID |
169569
|
| Appearance |
Solid powder
|
| Boiling Point |
490.7ºC
|
| Flash Point |
250.6ºC
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
16
|
| Complexity |
103
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ILRVASBWNRYBFD-UHFFFAOYSA-K
|
| InChi Code |
InChI=1S/CH3O5P.3Na.6H2O/c2-1(3)7(4,5)6;;;;;;;;;/h(H,2,3)(H2,4,5,6);;;;6*1H2/q;3*+1;;;;;;/p-3
|
| Chemical Name |
trisodium;phosphonatoformate;hexahydrate
|
| Synonyms |
Foscarnet trisodium hexahydrate (Trisodium phosphonoformate hexahydrate; Phosphonoformic acid trisodium salt hexahydrate)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3329 mL | 16.6644 mL | 33.3289 mL | |
| 5 mM | 0.6666 mL | 3.3329 mL | 6.6658 mL | |
| 10 mM | 0.3333 mL | 1.6664 mL | 3.3329 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
